about
Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosisAdvanced fault diagnosis methods in molecular networksCollaboration for rare disease drug discovery researchDuctular reaction correlates with fibrogenesis but does not contribute to liver regeneration in experimental fibrosis models.Monoclonal antibodies against autocrine motility factor suppress gastric cancer.The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family.Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model.Control of vascular smooth muscle function by Src-family kinases and reactive oxygen species in health and disease.A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition.New paradigms in clonal evolution: punctuated equilibrium in cancer.Complex chromosomal rearrangements involving five chromosomes in chronic myelogenous leukemia: A case reportEffect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative ColitisImatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia.Cellular characteristics of keratin 19-positive canine hepatocellular tumours explain its aggressive behaviour.Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets.Neuro-ophthalmic side effects of molecularly targeted cancer drugs.Molecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia.Overexpression of miR-202 re-sensitizes imatinib resistant chronic myeloid leukemia cells through targeting Hexokinase 2 (HK2).CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance.Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.In cancer cell lines inhibition of SCF/c-Kit pathway leads to radiosensitization only when SCF is strongly over-expressed.Imatinib derivatives as inhibitors of K562 cells in chronic myeloid leukemiaDynamics of human protein kinase Aurora A linked to drug selectivity
P2860
Q28080034-B83F6C4E-5BBC-406B-A085-CB12947319D9Q28543582-2E3B0DBB-FA67-450E-837B-FACAF3866E5EQ28650560-4C44D708-1EB3-4690-903B-EB6E576F6DC0Q33605760-A654CA46-D5EF-405F-91D6-3189632615C4Q33751147-88E2F90C-BA0E-4FA0-B3F5-B98E2A9D9079Q34699785-DC2C0EB6-FC75-4725-A9A7-9BBB68F6B061Q35816817-332D49B8-4FD2-4DC3-888C-22D810FA4C8DQ36125976-58C2904A-6BF1-44BF-8EDC-D12D2E372877Q36324677-E13921A9-4660-470E-B7FD-E5D14CD7D91AQ38266683-8FB8BAC0-F457-4892-A18E-3871B074B6F6Q38718622-06BDE495-8246-4C52-A326-9AB8DE287F27Q38860529-58D98FC7-BB25-4545-9BEB-FD4F47FC6CA1Q39643930-369B1F4A-7AA3-450B-B767-E6B97202D72BQ41826640-243D9EFC-5D65-4821-9A8D-FF85529CFE65Q42391586-6D94A521-1181-4D4E-BBF1-80BEA169F4A3Q43242400-461AB89A-FC00-491A-A209-F2D932195831Q47144472-AF6C7646-6492-4D66-89CE-2C1F5A1D7EDAQ47625145-60A56EC7-7846-4B0E-8AEB-A702532752C2Q50053531-47203F15-1DA0-4874-B4CE-A4651EF082D8Q52646158-F3AAB830-42B3-48F5-BBF1-D2EED5278494Q53703721-2ADA34FC-4E68-428B-BB23-AC7E899893ADQ55115766-6278D995-5161-4FC2-AEC5-EE3ED8E9F5B5Q55241601-314C1029-D34C-4533-9D38-6831A6820B2FQ56794302-5B125466-706B-44D2-A9DE-8F7C4F1CC839Q56889888-2222766B-4544-4DFB-84BC-59C1A8C55D3A
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Imatinib: a breakthrough of targeted therapy in cancer.
@ast
Imatinib: a breakthrough of targeted therapy in cancer.
@en
type
label
Imatinib: a breakthrough of targeted therapy in cancer.
@ast
Imatinib: a breakthrough of targeted therapy in cancer.
@en
prefLabel
Imatinib: a breakthrough of targeted therapy in cancer.
@ast
Imatinib: a breakthrough of targeted therapy in cancer.
@en
P2860
P356
P1476
Imatinib: a breakthrough of targeted therapy in cancer.
@en
P2093
Naveed Iqbal
P2860
P304
P356
10.1155/2014/357027
P50
P577
2014-05-19T00:00:00Z